These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 27307418)

  • 1. Drug companies settle claim of misleading doctors on cancer survival data.
    Dyer O
    BMJ; 2016 Jun; 353():i3361. PubMed ID: 27307418
    [No Abstract]   [Full Text] [Related]  

  • 2. What have we learnt from Vioxx?
    Krumholz HM; Ross JS; Presler AH; Egilman DS
    BMJ; 2007 Jan; 334(7585):120-3. PubMed ID: 17235089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes.
    Fraser A
    N Z Med J; 2017 Mar; 130(1451):11-20. PubMed ID: 28253240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant TKIs in NSCLC: what can we learn from RADIANT?
    Hirsch FR; Bunn PA
    Nat Rev Clin Oncol; 2015 Dec; 12(12):689-90. PubMed ID: 26552954
    [No Abstract]   [Full Text] [Related]  

  • 5. Rapid improvement of psoriasis in a patient with lung cancer after treatment with erlotinib.
    Goepel L; Jacobi A; Augustin M; Radtke MA
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):e311-e313. PubMed ID: 29430731
    [No Abstract]   [Full Text] [Related]  

  • 6. Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure.
    Womack JP; Varella-Garcia M; Camidge DR
    J Thorac Oncol; 2015 Dec; 10(12):e115-8. PubMed ID: 26709484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion.
    Kocoglu H; Karaca M; Turkay R; Tural D
    J BUON; 2016; 21(3):754-5. PubMed ID: 27569104
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).
    Yamada K; Azuma K; Takeshita M; Uchino J; Nishida C; Suetsugu T; Kondo A; Harada T; Eida H; Kishimoto J; Eriguchi G; Takayama K; Nakanishi Y; Sugio K
    Anticancer Res; 2016 Jun; 36(6):2881-7. PubMed ID: 27272800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
    Kelly K; Altorki NK; Eberhardt WE; O'Brien ME; Spigel DR; Crinò L; Tsai CM; Kim JH; Cho EK; Hoffman PC; Orlov SV; Serwatowski P; Wang J; Foley MA; Horan JD; Shepherd FA
    J Clin Oncol; 2015 Dec; 33(34):4007-14. PubMed ID: 26324372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET...
    Scagliotti GV; Di Maio M
    Ann Oncol; 2015 Oct; 26(10):2007-9. PubMed ID: 26265168
    [No Abstract]   [Full Text] [Related]  

  • 11. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.
    Hornberger J; Hirsch FR; Li Q; Page RD
    Lung Cancer; 2015 May; 88(2):223-30. PubMed ID: 25804732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Predictive value of the early metabolic response in patients with advanced-stage non-small cell lung cancer].
    Moreno C; Mourelo S; Soler M; Moragas M; Riera E; Garcia JR
    Rev Esp Med Nucl Imagen Mol; 2014; 33(5):324-5. PubMed ID: 24418117
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M; Okamoto I; Nakagawa K
    Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations.
    López-Ayllón BD; de Castro-Carpeño J; Rodriguez C; Pernía O; Ibañez de Cáceres I; Belda-Iniesta C; Perona R; Sastre L
    Int J Clin Exp Pathol; 2015; 8(3):2888-98. PubMed ID: 26045797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung cancer survival only increases by a small amount despite recent treatment advances.
    Bagcchi S
    Lancet Respir Med; 2017 Mar; 5(3):169. PubMed ID: 28169198
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of non-small cell lung cancer: focus on erlotinib. Foreword.
    Cappuzzo F
    Drugs; 2012 Jun; 72 Suppl 1():1-2. PubMed ID: 22712791
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceutical companies liable for fraudulent research by subcontractors.
    Nolan KJ
    Drug Discov Today; 2004 Feb; 9(4):153-4. PubMed ID: 14960392
    [No Abstract]   [Full Text] [Related]  

  • 19. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
    Comis RL
    Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
    [No Abstract]   [Full Text] [Related]  

  • 20. [Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
    Protsenko SA; Rudakova AV
    Vopr Onkol; 2015; 61(4):676-80. PubMed ID: 26571844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.